Discover verified cancer discoveries

Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.

Filter discoveries

Results

Active filters:Clear all

1 verified discovery matches your filters.

Adding lenvatinib and pembrolizumab to TACE improves progression-free survival in liver cancer, but the trial’s overall-survival goal was not met

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Liver Cancer
Published
August 13, 2026

In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with…

Primary source cited

Last reviewed